FDA rejects MDMA-assisted therapy for PTSD
The FDA recently made the decision to reject the use of MDMA-assisted therapy for the treatment of PTSD, citing a myriad of concerns including poorly designed studies and allegations of sexual misconduct. As someone who works in the clinical trial space, I understand the strict guidelines and the importance of well-designed studies when it comes to getting approval from regulatory bodies like the FDA. It’s clear that the issues within the studies conducted for MDMA therapy need to be addressed before any progress can be made.
The therapeutic potential of MDMA for individuals struggling with PTSD is undeniable. I’ve heard firsthand accounts of the emotional breakthroughs and healing that can occur when utilizing this drug in a therapeutic setting.… Continue reading
John Q. Hosedrinker